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Background: Little is known about the effect of social support on nonadherence in persons 
with schizophrenia, especially in developing Asian countries where social support is considered 
to be imperative. Additionally, the role of depression as a mediator in the association between 
social support deficits and nonadherence has not been evaluated.
Methods: This was a cross-sectional study conducted in 75 participants at a university hospital 
in Thailand. Logistic regression was used to determine whether depression and a deficit in social 
support were associated with nonadherence, and whether depression mediated this association.
Results: There were strong relationships between nonadherence and major depressive episodes 
(odds ratio [OR] 9.5, confidence interval [CI] 2.3–38.9), living alone (OR 21.8, CI 3.5–143.0), 
and dissatisfaction with support from family (OR 10.0, CI 1.9–53.1). The OR of the association 
between social support deficits and nonadherence decreased by nearly one half after adjusting 
for depression.
Discussion: Depression and social support deficits were significantly associated with nonad-
herence in persons with schizophrenia. Depression is important in mediating the association 
between social support deficits and nonadherence. Enhancing social support, as well as early 
detection and effective intervention for depression should be emphasized in interventions to 
improve adherence in persons with schizophrenia.
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Introduction
Antipsychotic drugs have been proved to be effective in treating persons with schizo-
phrenia, yet nonadherence with the drugs ranges from 20% to 89%.1,2 Nonadherence 
often leads to negative consequences, including relapse, rehospitalization, poor functional 
outcomes, and suicide.3,4
Several factors have been found to be associated with nonadherence, including 
illness-related factors (eg, severity of symptoms, insight, duration of illness), treatment-
related factors (eg, type of antipsychotic, side effects), and patient-related factors 
(eg, stigma, level of education, attitude toward illness, substance abuse).5 Depression 
has also been recognized as one of the strongest predictors of nonadherence in persons 
with schizophrenia6 and, in turn, nonadherence with antipsychotic drugs more than 
triples the suicide risk in these persons.7
Depression is common in the course of schizophrenia. The lifetime prevalence 
of major depressive episodes in schizophrenia has been estimated to be around 60%, 
and the point prevalence ranges widely from 10% to 83%, depending on the clinical 
setting, assessment, duration of study, and characteristics of the study population.8,9 Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Bartels and Drake categorized depressive symptoms in 
schizophrenia into three subtypes, ie, depressive symptoms 
secondary to general medical or substance-related factors, 
depressive symptoms occurring with acute psychotic episode, 
and depressive symptoms occurring without acute psychotic 
symptoms (such as prodromal symptoms, post-psychotic 
symptoms, and negative symptoms).10
Hudson et al found that lack of social support is one of the 
most common barriers to adherence reported by persons with 
schizophrenia,13 although some studies reported insignificant 
associations between social support and nonadherence.14–16 
Because the lack of social support from family and neighbors 
is associated with suicide in persons with schizophrenia,11 
depression may mediate the association between social sup-
port deficit and nonadherence. Social support deficit may lead 
to depression via decreased self-esteem, coping skills, and 
resilience, as well as an increase in experience of stigma.11,12 
In Thai culture, which is the focus of this paper, persons with 
schizophrenia generally live with their family members. 
Therefore, social support is considered critical for Thai 
persons with schizophrenia because they receive financial as 
well as emotional support from the family. However, little 
is known about the effect of social support on nonadherence 
in persons with schizophrenia because limited aspects of 
social support have been studied. Moreover, social support 
may vary from one culture to another, which may limit 
comparability of findings across cultures, and modification to 
measurement strategies might be required.17 In addition, the 
role of depression in the association between social support 
deficits and nonadherence in persons with schizophrenia has 
not been evaluated.
The purposes of this study were to assess the independent 
association of depression and social support deficit with 
nonadherence to antipsychotic drugs, and to evaluate the 
mediating effect of depression on the association between 
social support deficit and nonadherence to antipsychotic 
drugs. We hypothesized that depression and social support 
deficit were independently associated with nonadherence, 
and that the effect of social support deficit on nonadherence 
was mediated by depression.
Methods
This was a cross-sectional study conducted at an outpatient 
clinic of a university hospital in Chiang Mai, Thailand. We 
estimate the sample size required at 90% power and 5% sig-
nificance to be 72 participants. Therefore, after approval by 
the Ethics Committee, Faculty of Medicine, Chiang Mai Uni-
versity, 75 participants were recruited from December 2009 
to February 2010. The inclusion criteria were Thai-speaking, 
aged 18 years or over, diagnosis of schizophrenia according 
to Diagnostic and Statistical Manual of Mental Disorders, 
4th Edition, Text Revision (DSM-IV-TR),18 and receiving oral 
antipsychotic drugs. The exclusion criterion was receiving 
depot antipsychotic within the past month.
We used a clinician-rated visual analog scale (0%–100%) 
with an 80% cut-off point4 for evaluating nonadherence in the 
past month. Major depressive episodes were diagnosed by 
psychiatrists according to DSM-IV-TR.18 Social support was 
derived from the scale of six social support deficits (SSDs) 
which had been found to be highly salient to depression in a 
previous study.19 These social support deficits were defined 
as living alone, seeing a relative less often than once a week, 
lack of reciprocity with neighbours, lack of reciprocity 
between extended family members, relationship difficulty 
with one or more relatives, and dissatisfaction with support 
from family.
The association of nonadherence against each baseline 
characteristic was analyzed using Chi-square tests and logistic 
regression (P , 0.05). Odds ratios (ORs) and 95% confidence 
intervals (CIs) were calculated using logistic regression for 
the association between depression, social support deficits, 
and nonadherence. The association between social support 
and nonadherence were reported before and after adjustment 
for depression to identify the mediating effect of depression. 
The association between depression and nonadherence were 
reported before and after adjustment for age, gender, marital 
status, and income which were chosen a priori as they might 
associate with depression or nonadherence and, therefore, 
confound the association.19
Results
Of the 75 participants included in the study, 26 (34.7%) were 
male, 23 (30.7%) were married, 41 (54.7%) had completed at 
least high school, and 36 (48.0%) were working. The mean 
age was 46.8 ± 14.1 years in the adherence group and 
42.2 ± 10.6 years in the nonadherence group. The baseline 
characteristics significantly associated with nonadherence 
were type of antipsychotic drugs, side effects, and   satisfaction 
with treatment (Table 1).
The prevalence of nonadherence in the current study 
was 16.0%. Sixteen percent of the participants had major 
depressive episodes. Those with major depressive episodes 
were 9.5 times more likely to be nonadherent to antipsychotic 
drugs than those without depression before adjustment. The 
odds association was still significant after adjustment for age, 
gender, marital status, and income (Table 2).Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Of all persons with schizophrenia, 9.3% lived alone, 
13.3% saw a relative less often than once a week, 10.7% 
reported lack of reciprocity with neighbors, 9.3% felt that 
members in the family did not care about each other, 12% 
had experienced upset in a relationship with a relative, and 
9.3% were not satisfied with the support they received from 
their relatives. Two out of the six social support deficits were 
significantly associated with nonadherence, including living 
alone and dissatisfaction with support from family. However, 
after adjustment for depression, the association between 
dissatisfaction with support from family and   nonadherence 
became nonsignificant. Forty-three percent of the   participants 
had at least one social support deficit. Those with at least 
one social support deficit were 5.2 times more likely to be 
  nonadherent to antipsychotic drugs than those without a 
social support deficit. The odds of nonadherence dropped 
to 3.1 and were not significant after being adjusted for 
  depression (Table 3).
Discussion
Our study shows that nonadherence to antipsychotic drugs in 
schizophrenia is a complex and multifactorial phenomenon. 
Table 1 Baseline characteristics and nonadherence
Baseline characteristic Total 
(n = 75)  
n (%)
Adherent 
(n = 63)  
n (%)
Nonadherent 
(n = 12)  
n (%)
P value
gender 
  Male 
  Female
 
26 (34.7) 
49 (35.3)
 
20 (31.7) 
43 (68.3)
 
6 (50.0) 
6 (50.0)
 
0.321 
Age (years) 
  #40 
  .40
 
28 (37.3) 
47 (62.7)
 
22 (34.9) 
41 (65.1)
 
6 (50.0) 
6 (50.0)
 
0.346 
Marital status 
  Married 
  Single, widowed, or divorced
 
23 (30.7) 
52 (69.3)
 
20 (31.7) 
43 (68.3)
 
3 (25.0) 
9 (75.0)
 
0.745 
income (Baht/month) 
  no income 
  #10,000 
  .10,000
 
33 (44.0) 
24 (32.0) 
18 (24.0)
 
28 (44.4) 
18 (28.6) 
17 (27.0)
 
5 (41.7) 
6 (50.0) 
1 (8.3)
 
0.232
Work status 
  Working 
  not working or being a housewife
 
39 (52.0) 
36 (48.0)
 
34 (54.0) 
29 (46.0)
 
5 (41.7) 
7 (58.3)
 
0.434
Duration of illness 
  0–10 years 
  .10 years
 
37 (49.3) 
28 (50.7)
 
29 (46.0) 
34 (54.0)
 
8 (66.7) 
4 (33.3)
 
0.190
Antipsychotic 
  Typical 
  Atypical
 
38 (50.7) 
37 (49.3)
 
28 (44.4) 
35 (55.6)
 
10 (83.3) 
2 (16.7)
 
0.014
number of side effect 
  0–1 
  .1
 
31 (41.3) 
44 (58.7)
 
30 (47.6) 
33 (52.4)
 
1 (8.3) 
11 (91.7)
 
0.012
Satisfaction with treatment 
  Most satisfied 
  Very satisfied 
  Medium satisfied 
  Less satisfied 
  Not satisfied
 
34 (45.3) 
29 (38.7) 
9 (12) 
2 (2.7) 
1 (1.3)
 
31 (49.2) 
25 (39.7) 
6 (9.5) 
0 (0) 
0 (0)
 
3 (25.0) 
4 (33.0) 
3 (25.0) 
2 (16.7) 
1 (8.3)
 
0.007
Table 2 The association between depression and nonadherence
Depression n 
(n = 75)
% 
Nonadherence
Unadjusted 
OR (95% CI)
Adjusted 
ORa (95% CI)
noncase 62 9.5 1. 0  1. 0 
case 12 50 9.5 (2.3–38.9) 8.3 (1.9–35.8)
Note: aAdjusted for age, sex, marital status, and income.
Abbreviations: OR, odds ratio; CI, confidence interval. Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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The findings confirm the relationship between depression, 
social support deficit, as well as other factors, including 
type of antipsychotic drugs, side effects, and satisfaction   
with nonadherence in persons with schizophrenia.
Depression may lead to nonadherence via impairing 
cognitive functioning, which affect a person’s ability to fol-
low through with treatment.20,21 Moreover, because positive 
beliefs in the benefits of treatment are important for adher-
ence, pessimistic thoughts about the illness and loss of 
faith in treatment which are commonly found in depressed 
persons11 may lead to nonadherence. Evidence of depression 
affecting nonadherence has been found in other illnesses, 
including infectious disease, diabetes, heart disease, and 
osteoporosis.22–25 Because persons with schizophrenia already 
suffer from negative symptoms, the impact of depression on 
reducing motivation, which associates with nonadherence,26 
might be stronger than in other patient groups.15
Of the six social support deficits, living alone was the 
strongest factor associated with nonadherence, with the OR 
as high as over 20; however, the association between living 
alone and nonadherence decreased by nearly a half after 
being adjusted for depression. The impact of depression 
was similar in the association between the number of social 
support deficits and nonadherence. Taken together, our find-
ings suggest that social support deficits are risk factors for 
nonadherence in schizophrenia, and that the associations 
may be partially mediated by depression, thereby adding to 
the limited knowledge about the relationship between social 
support, depression, and nonadherence in schizophrenia.
Apart from being mediated by depression, social support 
deficit may lead to nonadherence directly via decreased cop-
ing skills, motivation, and resilience, as well as increased 
experience of stigma and emotional conflict.12,27 Persons 
who live alone may lack medication supervision and have 
difficulty accessing medical care.1 In addition, it was found 
that lack of support from family might hinder persons with 
schizophrenia in achieving rehabilitation.28
Our findings are in line with the review by Lacro et al 
which reported that age, gender, marital status, and duration of 
illness were not associated with nonadherence.1 About half of 
Thai persons with schizophrenia in this study received typical 
antipsychotic drugs. This percentage is higher than in Western 
countries which mostly use atypical ones.29,30 We found that 
adherence with atypical antipsychotic drugs was significantly 
better than with typical ones. This parallels previous studies 
which found that there was an overall trend toward greater 
adherence among persons receiving atypical antipsychotic 
drugs.1,31 Our findings are also consistent with those of a previ-
ous study showing that individuals who switched from a   typical 
to an atypical antipsychotic drug were more adherent than 
those who had their typical antipsychotic drug maintained.32
Typical antipsychotic drugs are more likely to produce 
extrapyramidal side effects and akathisia, which may directly 
lead to nonadherence. It is also suggested that typical antip-
sychotic drugs are depressogenic by blocking dopamine 
2 receptors33 and may lead to nonadherence via depression. 
Fewer side effects, as well as the effectiveness of atypical 
antipsychotic drugs in managing psychotic symptoms, might 
make it more likely that persons will continue their treatment. 
Thus, the choice of antipsychotic drug affects adherence to 
those drugs.
This study, in parallel with previous studies,34,35 shows 
that side effects impact antipsychotic adherence. A study 
by Yamada et al found that the most common reason for 
nonadherence in Japanese persons with schizophrenia was 
“distressed by side effects”.36 In contrast, studies of persons 
with first-episode schizophrenia reported negative findings.6,37 
Perkins et al suggested that stage of illness and experience 
with antipsychotic side effects may have an impact on the 
contribution of side effects to nonadherence.6
Table 3 The association between social support deficits and nonadherence
Six social support deficits n 
(n = 75)
% 
Nonadherence
Unadjusted 
OR (95% CI)
Adjusted 
ORa (95% CI)
Living alone 7 71.4 21.8 (3.5–134.0) 13.4 (1.9–94.3)
Seeing a relative less often than once a week 10  50.0 6.1 (0.8–48.4) 3.5 (0.3–37.4)
Lack of reciprocity with neighbors 8  25.0 1.9 (0.3–10.7) 1.6 (0.2–11.0)
Lack of reciprocity between extended family members 7  28.6 2.3 (0.4–13.6) 1.1 (0.5–8.9)
Difficulty in relationship with one or more relatives 9  11.1 0.6 (0.1–5.5) 0.4 (0.04–4.8)
Dissatisfaction with support from family 7 57.1 10.0 (1.9–53.1) 5.3 (0.8–34.0)
Number of social support deficits
No social support deficit 43 7.0 1.0 1.0
At least one social support deficit 32 28.1 5.2 (1.3–21.2) 3.1 (0.7–14.1)
Note: aAdjusted for depression.
Abbreviations: OR, odds ratio; CI, confidence interval.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Although this study leads to a better   understanding of the 
association between nonadherence, social support,   depression, 
and other variables, certain limitations exist. Firstly, the 
direction of causality among variables cannot be determined 
due to the cross-sectional study design. It is   possible that 
there might be a vicious cycle whereby depression and 
social support deficit cause nonadherence which, in turn, 
worsen depression and social support deficit. In   addition, 
  nonadherence may change over time, although some studies 
have found it to be quite stable.38
Secondly, nonadherence was assessed based on psychia-
trist judgment only, so it may have been underestimated. 
Moreover, psychiatrists’ judgment of adherence may have 
been biased by the clinical state of the patients.39
Thirdly, it should be borne in mind that the social   support 
deficit scale was developed to assess social support deficit in 
older adults, and therefore, measurement error might have 
occurred through the adaptation of the social support deficit 
scale to a different sample. Moreover, use of a clinician-rated 
visual analog scale, although easily assessed and commonly 
used to assess adherence, may have limited validity and 
underestimated nonadherence. This limitation might explain 
the relatively low prevalence of nonadherence found in this 
study and might be the reason why we did not find associa-
tions between some of the social support deficit subscale 
items and nonadherence. However, this would not explain 
our positive findings.
Fourthly, the small sample size might limit our positive 
findings and might explain the low frequency of comorbid 
depression found in this study, although the result is in line 
with the findings reported in a previous survey in Thailand.40 
In addition, research in the hospital setting might lead to selec-
tion bias because individuals who are nonadherent are more 
likely to be lost to follow-up during the treatment process, and 
the particular sample characteristics from a   university   hospital 
in Thailand might reduce   generalizability to other persons 
with schizophrenia in different settings. Future research in a 
community setting, conducted in a larger number of persons 
with schizophrenia or other   psychotic disorders, is necessary 
for a better understanding of nonadherence.
In conclusion, this study shows that depression and social 
support deficits were significantly associated with nonadher-
ence in persons with schizophrenia. Depression is important 
in mediating the association between social support and 
nonadherence in persons with schizophrenia. Other baseline 
characteristics found to be associated with nonadherence 
were receiving typical antipsychotic drugs, having more 
than one side effect, and being less satisfied with treatment. 
Enhancing social support, which is a modifiable factor, 
should be emphasized in intervention to improve adherence 
in persons with schizophrenia. Early detection and effective 
intervention for depression, as well as concern about drug 
side effects and patient satisfaction might be useful in dealing 
with nonadherence in persons with schizophrenia.
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